View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
EUR 175.94
VTRS VIATRIS INC.

Viatris Inc.: Viatris expects 2025 earnings decline after FDA blocks U...

Viatris expects a loss of roughly $500 million in revenues and $385 million in EBITDA in 2025.

02/27/25 February 27, 2025 1 EN
EUR 219.93
VTRS VIATRIS INC.

Viatris Inc.: Update to credit analysis following ratings affirmation

Viatris' credit profile reflects its considerable size and global scale, along with moderate financial leverage, and strong cash flows, offset by core business price erosion and competition.

09/23/24 September 23, 2024 1 EN
EUR 219.93
VTRS VIATRIS INC.

Viatris Inc.: Update to credit analysis following ratings affirmation

Our credit view of this issuer reflects its considerable size and global scale, constrained by its elevated financial leverage.

10/16/23 October 16, 2023 1 EN
EUR 219.93
VTRS VIATRIS INC.

Viatris Inc.: Evolving strategies to improve growth present execution ...

Viatris' credit profile reflects its considerable size and global scale, constrained by its elevated financial leverage and growth pressures related to generic drug pricing and mature brands

07/21/23 July 21, 2023 1 EN
EUR 175.94
VTRS VIATRIS INC.

Viatris Inc.: Strategic initiatives support credit profile but have ex...

Eyecare acquisitions and planned asset divestitures represent ongoing strategy to reshape the business for long-term growth

11/07/22 November 7, 2022 1 EN
EUR 158.35
VTRS VIATRIS INC.

Moody's: Viatris' biosimilars transaction is credit positive but tempe...

Announcement: Moody's: Viatris' biosimilars transaction is credit positive but tempered by core earnings pressure and ongoing cash outlays. Global Credit Research- 28 Feb 2022. New York, February 28, 2022-- Moody's Investors Service commented that Viatris Inc.' s formation of a biosimilars partnership with Biocon Limited is credit positive for Viatris, based on a substantial cash inflow of $2 billion that will facilitate debt reduction.

03/01/22 March 1, 2022 1 EN
EUR 175.94
VTRS VIATRIS INC.

Viatris Inc.: Biosimilars transaction is credit positive, but tempered...

Accelerated debt reduction from the biosimilars transaction helps to offset continuing business challenges

02/28/22 February 28, 2022 1 EN
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch